Overview

* Scholar Rock ( SRRK ) reports Q2 net loss of $110 mln, no revenue recorded

* Cash reserves expected to support operations into 2027

Result Drivers

* COSTS INCREASE - R&D costs increase $20 mln was due to higher drug supply manufacturing costs, employee related expenses

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$110.03

Income mln

Q2 Basic -$0.98

EPS

Q2 -$112.11

Income mln

from

Operatio

ns

Q2 $112.11

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Scholar Rock Holding Corp ( SRRK ) is $52.00, about 28.9% above its August 5 closing price of $36.98

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)